0001181431-11-018858.txt : 20110317
0001181431-11-018858.hdr.sgml : 20110317
20110317203654
ACCESSION NUMBER: 0001181431-11-018858
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110315
FILED AS OF DATE: 20110317
DATE AS OF CHANGE: 20110317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CONNAUGHTON JOHN
CENTRAL INDEX KEY: 0001213395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11239
FILM NUMBER: 11696541
MAIL ADDRESS:
STREET 1: BAIN CAPITAL PARTNERS LLC
STREET 2: 111 HUNTINGTON AVE
CITY: BOSTON
STATE: MA
ZIP: 02199
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: HCA Holdings, Inc.
CENTRAL INDEX KEY: 0000860730
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-GENERAL MEDICAL & SURGICAL HOSPITALS, NEC [8062]
IRS NUMBER: 273865930
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE PARK PLZ
CITY: NASHVILLE
STATE: TN
ZIP: 37203
BUSINESS PHONE: 6153449551
MAIL ADDRESS:
STREET 1: ONE PARK PLAZA
CITY: NASHVILLE
STATE: TN
ZIP: 37203
FORMER COMPANY:
FORMER CONFORMED NAME: HCA INC/TN
DATE OF NAME CHANGE: 20010627
FORMER COMPANY:
FORMER CONFORMED NAME: HCA THE HEALTHCARE CO
DATE OF NAME CHANGE: 20010419
FORMER COMPANY:
FORMER CONFORMED NAME: COLUMBIA HCA HEALTHCARE CORP
DATE OF NAME CHANGE: 20000502
4
1
rrd305784.xml
FORM 4
X0303
4
2011-03-15
0
0000860730
HCA Holdings, Inc.
HCA
0001213395
CONNAUGHTON JOHN
C/O BAIN CAPITAL PARTNERS, LLC
111 HUNTINGTON AVENUE
BOSTON
MA
02199
1
0
1
0
Common Stock, Par Value $0.01
2011-03-15
4
S
0
15619633
28.9125
D
89502367
I
See Footnotes
The shares of HCA Holdings, Inc. ("HCA") reported on this Form 4 are held of record by Hercules Holding II, LLC ("Hercules II"). Hercules II is held by a private investor group, including affiliates of Bain Capital Investors, LLC ("BCI"), Kohlberg Kravis & Roberts & Co. LLC and Merrill Lynch Global Private Equity, and affiliates of HCA founder Dr. Thomas F. Frist, Jr.
Includes 14,503,009 shares of common stock of HCA indirectly sold by Bain Capital Integral Investors 2006, LLC ("Integral 2006") by virtue of its membership in Hercules II. Mr. Connaughton is Managing Director BCI. Because BCI is the administrative member of Integral 2006, Mr. Connaughton may be deemed to share voting and dispositive power with respect to the 83,174,817 shares of Common Stock of HCA indirectly owned by Integral 2006 by virtue of its membership in Hercules Holding II, LLC ("Holdings"). Mr. Connaughton disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Includes 105,869 shares of common stock of HCA indirectly sold by BCIP TCV, LLC ("BCIP TCV") by virtue of its membership in Hercules II. Because BCI is the administrative member of BCIP TCV, Mr. Connaughton may be deemed to share voting and dispositive power with respect to the 599,929 shares of Common Stock of HCA indirectly owned by BCIP TCV by virtue of its membership in Hercules II. Mr. Connaughton disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Includes 1,010,755 shares of common stock of HCA indirectly sold by Bain Capital Hercules investors, LLC ("Hercules Investors" together with BCI, Integral 2006 and BCIP TCV, the "Bain Capital Entities"), by virtue of its membership in Hercules II. Because BCI is the administrative member of Hercules Investors, LLC, Mr. Connaughton may be deemed to share voting and dispositive power with respect to the 5,727,621 shares of Common Stock of HCA indirectly owned by Hercules Investors by virtue of its membership in Holdings. Mr. Connaughton disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
As a result of the relationships described in the forgoing footnotes, the Bain Capital Entities may be deemed to share voting and dispositive power with respect to the 357,440,258 shares of Common Stock of HCA held by Hercules II. Each of the Bain Capital Entities disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.
This amount represents a price to the public of $30.00 per share of common stock, less an underwriting discount of $1.0875.
/s/ John Connaughton
2011-03-17